SummaryRMgm-5578
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption, Introduction of a transgene, Introduction of a transgene |
Reference (PubMed-PMID number) | Not published (yet) |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA cl15cy1 |
Other information parent line | A reference wild type clone from the ANKA strain of P. berghei (PubMed: PMID: 17406255). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Balakrishnan A, Billker O |
Name Group/Department | The Laboratory for Molecular Infection Medicine Sweden |
Name Institute | Umeå University |
City | Umeå |
Country | Sweden |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5578 |
Principal name | fd1-cas9-bfp |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Infertile females, fertile males. |
Fertilization and ookinete | Infertile females, fertile males. Complete loss in the ability to form oocysts in mosquitoes |
Oocyst | Complete loss in the ability to form oocysts in mosquitoes |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Abstract: In the homing screen (using crosses between gametocytes of two lines making only male or only female gametocytes (fd1; RMgm-5578) or male development 4 (md4; RMgm-5579)) it was found that two of three oocyst-expressed genes of unknown function, PBANKA_0916000 and PBANKA_1006400 showed a marked homing effect warranting further investigation. How mutants behave in the homing screen may be confounded by factors other than gene function, such as the efficiency of gRNAs, how much transcript or protein a zygote inherits from the female parent and how fast these turn over. To validate the result of the pilot screen we studied PBANKA_0916000 (RMgm-5580), a poorly understood gene with a new phenotype, which we find encodes a chloroquine resistance transporter like (CRTL) protein. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1454800 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1241400 | ||||||||||||||||||||||||
Gene product | RNA-binding protein, putative | ||||||||||||||||||||||||
Gene product: Alternative name | fd1 (female-defective 1) protein | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||||||||
Additional remarks genetic modification | Fluorescence and drug resistance marker-free single-sex lines were generated by disrupting PBANKA_1454800 (fd1) or PBANKA_0102400 (md4), respectively6 using a CRISPR-RGR strategy (ribozyme guide ribozyme) with two sgRNAs to target the gene of interest (see also RMgm-4632) in the P. berghei clone cl15cy1. To construct a plasmid to express a CRISPR-Cas9 transgene, we modified the existing CRISPR-RGR strategy with two single guide RNAs (sgRNAs) to target the gene of interest. The sgRNAs were designed using Benchling, and the sgRNA cassette (containing the gRNA along with RGR) was synthesised (Azenta Life Sciences). Subsequently, the sgRNA cassette was cloned into the cas9 plasmid (MH_046) which carries a hdhfr selection cassette to generate PL_HC_014 (gRNA plasmid targeting md4) and PL_HC015 (gRNA plasmid targeting fd1). DNA fragments encoding an hsp70 promoter, Nterminal flag tagged cas9, bfp and dhfr 3’UTR were cloned into a plasmid and flanked with 500 bp sequences targeting either fd1 or md4 locus. To generate the repair template, hsp70 promoter, cas9, bfp and Pbdhfr 3’UTR gene sequences were amplified from plasmids Pb_MH21 and R6K-GW-BFP (PL_HC_001) respectively using Advantage 2 Polymerase Mix (TaKaRa). Individual fragments were assembled by stitch PCR, digested with Kpn1 and Sac11, and ligated into an intermediated vector pMisc 017) to generate PL_HC013. The cas9-bfp fragment was sub-cloned into two pre-synthesized plasmids (Azenta Life Science) containing 500 bp sequences upstream and downstream of either fd1 or md4 gene locus to generate plasmid carrying repair template PL_HC_018 and PL_HC_017 respectively. To generate transgenic single-sex lines expressing Cas9, P. berghei schizonts were co-transfected with 1 μg of the Cas9-sgRNA vector and linearized cas9bfp repair template targeting either the md4 or fd1 gene locus. Transfected parasites were promptly injected intravenously into BALB/c mice and were subjected to selection with 0.07 mg/mL of pyrimethamine in drinking water starting from day one post-infection. Pyrimethamine selection was terminated on Day 5, and mice were administered 5-fluorocytosine (1 mg/mL, Sigma) via drinking water to eliminate the CRISPR plasmid carrying the dhfr/yfcu selection cassette (negative selection). Insertion of cas9 bfp in the md4 and fd1 gene loci was confirmed by PCR. Cas9-BFP expression in the nucleus was visualised by live imaging of infected cells. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | Cas9, N-terminal flag-tagged | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||
Additional remarks genetic modification | Fluorescence and drug resistance marker-free single-sex lines were generated by disrupting PBANKA_1454800 (fd1) or PBANKA_010240o (md4), respectively6 using a CRISPR-RGR strategy (ribozyme guide ribozyme) with two sgRNAs to target the gene of interest (see also RMgm-4632) in the P. berghei clone cl15cy1. To construct a plasmid to express a CRISPR-Cas9 transgene, we modified the existing CRISPR-RGR strategy with two single guide RNAs (sgRNAs) to target the gene of interest. The sgRNAs were designed using Benchling, and the sgRNA cassette (containing the gRNA along with RGR) was synthesised (Azenta Life Sciences). Subsequently, the sgRNA cassette was cloned into the cas9 plasmid (MH_046) which carries a hdhfr selection cassette to generate PL_HC_014 (gRNA plasmid targeting md4) and PL_HC015 (gRNA plasmid targeting fd1). DNA fragments encoding an hsp70 promoter, Nterminal flag tagged cas9, bfp and dhfr 3’UTR were cloned into a plasmid and flanked with 500 bp sequences targeting either fd1 or md4 locus. To generate the repair template, hsp70 promoter, cas9, bfp and Pbdhfr 3’UTR gene sequences were amplified from plasmids Pb_MH21 and R6K-GW-BFP (PL_HC_001) respectively using Advantage 2 Polymerase Mix (TaKaRa). Individual fragments were assembled by stitch PCR, digested with Kpn1 and Sac11, and ligated into an intermediated vector pMisc 017) to generate PL_HC013. The cas9-bfp fragment was sub-cloned into two pre-synthesized plasmids (Azenta Life Science) containing 500 bp sequences upstream and downstream of either fd1 or md4 gene locus to generate plasmid carrying repair template PL_HC_018 and PL_HC_017 respectively. To generate transgenic single-sex lines expressing Cas9, P. berghei schizonts were co-transfected with 1 μg of the Cas9-sgRNA vector and linearized cas9bfp repair template targeting either the md4 or fd1 gene locus. Transfected parasites were promptly injected intravenously into BALB/c mice and were subjected to selection with 0.07 mg/mL of pyrimethamine in drinking water starting from day one post-infection. Pyrimethamine selection was terminated on Day 5, and mice were administered 5-fluorocytosine (1 mg/mL, Sigma) via drinking water to eliminate the CRISPR plasmid carrying the dhfr/yfcu selection cassette (negative selection). Insertion of cas9 bfp in the md4 and fd1 gene loci was confirmed by PCR. Cas9-BFP expression in the nucleus was visualised by live imaging of infected cells. | ||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0711900 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0818900 | ||||||||||||||||||
Gene product | heat shock protein 70 | ||||||||||||||||||
Gene product: Alternative name | HSP70 | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_1454800 | ||||||||||||||||||
Gene product | RNA-binding protein, putative | ||||||||||||||||||
Gene product: Alternative name | fd1 (female-defective 1) protein | ||||||||||||||||||
| |||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | Blue Fluorescence Protein (BFP) | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||
Additional remarks genetic modification | Fluorescence and drug resistance marker-free single-sex lines were generated by disrupting PBANKA_1454800 (fd1) or PBANKA_010240o (md4), respectively6 using a CRISPR-RGR strategy (ribozyme guide ribozyme) with two sgRNAs to target the gene of interest (see also RMgm-4632) in the P. berghei clone cl15cy1. To construct a plasmid to express a CRISPR-Cas9 transgene, we modified the existing CRISPR-RGR strategy with two single guide RNAs (sgRNAs) to target the gene of interest. The sgRNAs were designed using Benchling, and the sgRNA cassette (containing the gRNA along with RGR) was synthesised (Azenta Life Sciences). Subsequently, the sgRNA cassette was cloned into the cas9 plasmid (MH_046) which carries a hdhfr selection cassette to generate PL_HC_014 (gRNA plasmid targeting md4) and PL_HC015 (gRNA plasmid targeting fd1). DNA fragments encoding an hsp70 promoter, Nterminal flag tagged cas9, bfp and dhfr 3’UTR were cloned into a plasmid and flanked with 500 bp sequences targeting either fd1 or md4 locus. To generate the repair template, hsp70 promoter, cas9, bfp and Pbdhfr 3’UTR gene sequences were amplified from plasmids Pb_MH21 and R6K-GW-BFP (PL_HC_001) respectively using Advantage 2 Polymerase Mix (TaKaRa). Individual fragments were assembled by stitch PCR, digested with Kpn1 and Sac11, and ligated into an intermediated vector pMisc 017) to generate PL_HC013. The cas9-bfp fragment was sub-cloned into two pre-synthesized plasmids (Azenta Life Science) containing 500 bp sequences upstream and downstream of either fd1 or md4 gene locus to generate plasmid carrying repair template PL_HC_018 and PL_HC_017 respectively. To generate transgenic single-sex lines expressing Cas9, P. berghei schizonts were co-transfected with 1 μg of the Cas9-sgRNA vector and linearized cas9bfp repair template targeting either the md4 or fd1 gene locus. Transfected parasites were promptly injected intravenously into BALB/c mice and were subjected to selection with 0.07 mg/mL of pyrimethamine in drinking water starting from day one post-infection. Pyrimethamine selection was terminated on Day 5, and mice were administered 5-fluorocytosine (1 mg/mL, Sigma) via drinking water to eliminate the CRISPR plasmid carrying the dhfr/yfcu selection cassette (negative selection). Insertion of cas9 bfp in the md4 and fd1 gene loci was confirmed by PCR. Cas9-BFP expression in the nucleus was visualised by live imaging of infected cells. | ||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0711900 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0818900 | ||||||||||||||||||
Gene product | heat shock protein 70 | ||||||||||||||||||
Gene product: Alternative name | HSP70 | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_1454800 | ||||||||||||||||||
Gene product | RNA-binding protein, putative | ||||||||||||||||||
Gene product: Alternative name | fd1 (female-defective 1) protein | ||||||||||||||||||
| |||||||||||||||||||
top of page |